drugset / Trial / NCT00517569
Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety of GX-12 gene therapy combined with HAART in the HIV-1 infected patients and to investigate the efficacy with the value of plasma viral load and with CD4 counts and HIV-1 specific IFN-gamma expressed T-lymphocytes
Timeline
- Start
- 2006-08
- Primary completion
- 2009-12
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GX-12 | Other / unclassified | 4 mg | Intramuscular |
| Subject | GX-12 | Other / unclassified | 8 mg | Intramuscular |
| Subject | GX-12 | Other / unclassified | 16 mg | Intramuscular |